Coagadex
What Coagadex is used for
Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency. Coagadex is indicated in all age groups.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Coagadex
- Active substance
- human coagulation factor X
- Disease area
- Factor X Deficiency
- Medicine group
- Vitamin K and other hemostatics;Antihemorrhagics;coagulation factor X
- ATC code
- B02BD13
- Marketing authorisation holder
- Kedrion S.p.A.
- Authorised in the EU since
- 2016
Official information
In the USA
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Coagadex used for?
Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency. Coagadex is indicated in all age groups.
What is the active substance in Coagadex?
Coagadex contains human coagulation factor X.
Who makes Coagadex?
The EU marketing authorisation holder is Kedrion S.p.A..
Is Coagadex an orphan medicine?
Yes. Coagadex is designated an orphan medicine in the EU, for a rare disease (Factor X Deficiency).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU